A Second Life for Bayer HealthCare's Diabetes Drug in China
Published: Nov 28, 2011
November 23, 2011 -- China offers many different opportunities to global pharma – inexpensive APIs, drug development, a large market, to name a few very broad categories. For Bayer, China has given a second life to a 17-year-old diabetes drug, Glucobay. Glucobay, long off patent, is almost forgotten in the US. But it provided Bayer China with $283 million in revenues last year, an increase of 22% over the year before. More details....
Stock Symbol: (XETRA: BAY)